Aprea Therapeutics Inc (APRE)
5.03
-0.07
(-1.31%)
USD |
NASDAQ |
May 22, 16:00
5.01
-0.02
(-0.40%)
After-Hours: 20:00
Aprea Therapeutics SG&A Expense (Quarterly): 1.930M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.930M |
December 31, 2023 | 1.643M |
September 30, 2023 | 1.720M |
June 30, 2023 | 1.699M |
March 31, 2023 | 3.366M |
December 31, 2022 | 2.120M |
September 30, 2022 | 3.083M |
June 30, 2022 | 15.63M |
March 31, 2022 | 3.985M |
December 31, 2021 | 3.366M |
September 30, 2021 | 3.415M |
June 30, 2021 | 3.343M |
Date | Value |
---|---|
March 31, 2021 | 3.426M |
December 31, 2020 | 4.895M |
September 30, 2020 | 3.473M |
June 30, 2020 | 3.787M |
March 31, 2020 | 2.776M |
December 31, 2019 | 3.938M |
September 30, 2019 | 2.308M |
June 30, 2019 | 1.619M |
March 31, 2019 | 0.7293M |
December 31, 2018 | 0.5044M |
September 30, 2018 | 0.6237M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.619M
Minimum
Jun 2019
15.63M
Maximum
Jun 2022
3.576M
Average
3.355M
Median
SG&A Expense (Quarterly) Benchmarks
NeuBase Therapeutics Inc | 1.203M |
Stoke Therapeutics Inc | 10.22M |
NovaBay Pharmaceuticals Inc | 3.346M |
Palatin Technologies Inc | 2.033M |
iBio Inc | 2.722M |